Acute Ischemic Stroke is a new study from Decision Resources, Inc., that examines the pipeline of agents in development for acute ischemic stroke (IS) and details their clinical and commercial outlook. In 2000, there were more than 1.5 million incidents of acute IS in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). However, because of the dearth of specific pharmacological treatments for acute IS, only a fraction of IS sufferers were drug-treated in 2000.

(Photo: )

News from the IS pipeline over the past three years has continued to be disappointing. The failures of trials of several high-profile investigational neuroprotective drugs have left the door open for an agent capable of filling the unmet needs in acute IS treatment. Although the pipeline for acute IS remains slim, pharmaceutical manufacturers are aware of the problems that have plagued other agents and have taken steps to avoid these obstacles in their investigations of neuroprotective agents by designing trials that have a better chance of success.

One bright spot on the horizon is Millennium Pharmaceutical's proteasome inhibitor LDP-519 (PS-519). Although the agent has just entered Phase I trials, LDP-519 has captured the attention of thought leaders and industry watchers worldwide because it has unique characteristics that could be beneficial if its efficacy and safety are borne out.

Acute Ischemic Stroke offers invaluable market intelligence for pharmaceutical companies competing in this market, and is a part of Cognos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

Contact Frank Sama, 781.296.2553 (tel), 781.296.2525 (fax), or

In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,

Celebrex and Vioxx Vie for Osteoarthritis Market Leadership, According to a Decision Resources Study

View Now